Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
99207-0260-12 99207-0260 Imiquimod Aldara 50.0 mg/g Immunotherapy Immunomodulator Dermatological Agent Topical Feb. 27, 1997 June 30, 2022 No Longer Used
70121-1755-01 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1755-07 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1754-01 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1754-07 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
59572-0515-01 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-02 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-03 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
43598-0516-01 43598-0516 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
43598-0516-63 43598-0516 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use

Found 10,000 results in 2 milliseconds — Export these results